stockrow
Friday 6 November 2026
Export ILMN’s income statement to Excel — free account
Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.
- Revenue
- +4.15%
- EPS
- +49.0%
- Free cash flow
- +49.8%
- Total debt
- +80.0%
Quarter to September 2026, against a year earlier
213.33
5.33
+2.56%
Follow ILMN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
23.93 | 22.29 | 32.50 | 46.47 |
P/S ratio |
4.68 | 4.29 | 5.91 | 9.11 | |
P/FCF ratio |
22.19 | 19.67 | 28.99 | 39.66 | |
P/Operating CF |
63.33 | 65.26 | 132.09 | 98.63 | |
P/B ratio |
7.47 | 7.05 | 9.36 | 13.14 | |
Price to Tangible BV |
14.52 | 19.60 | 23.21 | 28.11 | |
EV/Sales |
4.76 | 4.48 | 6.09 | 9.31 | |
EV/EBITDA |
19.20 | 17.54 | 23.69 | 34.14 | |
EV/Operating CF |
19.16 | 17.45 | 24.99 | 34.36 | |
EV/FCF |
22.57 | 20.52 | 29.87 | 40.56 | |
Quick Ratio |
1.57 | 1.21 | 1.22 | 1.80 | |
Current Ratio |
2.08 | 1.75 | 1.80 | 2.63 | |
Net Debt/EBITDA |
(0.53) | 1.21 | 1.03 | 1.20 | |
Debt/Assets |
22.43% | 22.72% | 22.42% | 26.26% | |
Debt/Equity |
0.55 | 0.56 | 0.53 | 0.57 | |
Asset Turnover |
0.67 | 0.69 | 0.71 | 0.70 | |
Operating CF/Net income |
0.96 | 2.16 | 0.97 | 1.90 | |
Capex/Depreciation |
(0.83) | (0.55) | (0.57) | (0.56) | |
Interest Coverage |
7.77 | 8.71 | 10.21 | 12.71 | |
Research and Development Expense of Revenue |
20.62% | 22.00% | 21.74% | 21.61% | |
Selling, General and Administrative Expense of Revenue |
26.57% | 24.93% | 23.55% | 24.89% | |
Intangible Assets out of Total Assets |
0.20 | 0.26 | 0.25 | 0.25 | |
Share Based Compensation of Revenue |
5.44% | 5.50% | 6.30% | 6.55% | |
Graham Net Nets |
(0.03) | (0.06) | (0.04) | (0.02) | |
Graham Number |
46.54 | 46.65 | 47.83 | 52.54 | |
Earnings Yield |
4.18% | 4.49% | 3.08% | 2.15% | |
Free Cash Flow Yield |
4.51% | 5.09% | 3.45% | 2.52% | |
Revenue per Share |
7.48 | 7.13 | 7.68 | 7.48 | |
Operating CF per Share |
2.07 | 1.89 | 1.33 | 2.77 | |
Capex per Share |
(0.35) | (0.25) | (0.26) | (0.26) | |
Free Cash Flow per Share |
1.72 | 1.64 | 1.07 | 2.51 | |
Cash per Share |
10.54 | 7.55 | 7.74 | 8.85 | |
Shareholders Equity per Share |
17.57 | 17.49 | 18.79 | 20.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.57 | 17.49 | 18.79 | 20.83 | |
Free Cash Flow |
266.00 | 251.00 | 161.00 | 379.00 | |
Working Capital |
1,704.00 | 1,172.00 | 1,256.00 | 1,879.00 | |
Capital Expenditures |
(55.00) | (38.00) | (40.00) | (40.00) | |
Net Current Asset Value |
(632.00) | (1,145.00) | (978.00) | (632.00) | |
EV/EBIT |
25.62 | 23.10 | 30.99 | 43.98 | |
Capex to Sales |
0.05 | 0.03 | 0.03 | 0.04 | |
Price to Operating Income |
25.19 | 22.13 | 30.07 | 43.00 | |
| Other line items | |||||
Average Receivables |
794.50 | 718.50 | 732.50 | 733.50 | |
Average Payables |
230.50 | 212.50 | 215.00 | 229.50 | |
Average Inventory |
555.50 | 574.00 | 602.00 | 628.50 | |
Average Assets |
6,473.50 | 6,370.50 | 6,368.50 | 6,494.50 | |
Average Common Equity |
2,548.00 | 2,522.00 | 2,548.00 | 2,763.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026